MedPath

Quantumleap Healthcare Collaborative

Quantumleap Healthcare Collaborative logo
🇺🇸United States
Ownership
Private
Established
2005-01-01
Employees
11
Market Cap
-
Website
https://www.quantumleaphealth.org

Clinical Trials

5

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:2
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 1
2 (40.0%)

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Phase 2
Recruiting
Conditions
Ductal Carcinoma in Situ
Interventions
First Posted Date
2023-10-10
Last Posted Date
2025-06-27
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
400
Registration Number
NCT06075953
Locations
🇺🇸

Berkeley Outpatient Center, Berkeley, California, United States

🇺🇸

UCSF, San Francisco, California, United States

🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

and more 11 locations

PRE-I-SPY Phase I/Ib Oncology Platform Program

Phase 1
Recruiting
Conditions
Metastatic Breast Cancer
Metastatic
Hormone Receptor-positive Breast Cancer
Hormone Receptor Negative Breast Carcinoma
HER2 Low Breast Cancer
HER2 Low Breast Carcinoma
HER2-positive Breast Cancer
Metastatic Cancer
HER2-negative Breast Cancer
Solid Tumor, Adult
Interventions
First Posted Date
2023-05-22
Last Posted Date
2025-04-04
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
124
Registration Number
NCT05868226
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States

🇺🇸

The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

and more 4 locations

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Phase 1
Withdrawn
Conditions
Metastatic Breast Cancer
Metastatic Gastrointestinal Carcinoid Tumor
HER-2 Protein Overexpression
HER2-positive Breast Cancer
HER2 Low
SYD-985
SYD985
Vic-trastuzumab Duocarmazine
Metastatic Cancer
Metastatic
Interventions
Drug: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
First Posted Date
2020-10-26
Last Posted Date
2023-11-18
Lead Sponsor
QuantumLeap Healthcare Collaborative
Registration Number
NCT04602117
Locations
🇺🇸

University of Colorado Cancer Center, Aurora, Colorado, United States

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

First Posted Date
2020-07-27
Last Posted Date
2024-03-19
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
1500
Registration Number
NCT04488081
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

UC Davis Medical Center, Davis, California, United States

🇺🇸

UC Irvine Medical Center, Irvine, California, United States

and more 33 locations

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Phase 2
Recruiting
Conditions
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
Breast Neoplasms
Breast Tumors
HER2-positive Breast Cancer
Hormone Receptor Negative Tumor
Breast Cancer
Early-stage Breast Cancer
Interventions
First Posted Date
2010-01-05
Last Posted Date
2024-10-22
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
5000
Registration Number
NCT01042379
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

and more 33 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath